Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Busulfan, an alkylating agent administered prior to hematopoietic stem cell transplantation, has a narrow therapeutic range and wide variability in metabolism. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for rapid and accurate quantification of plasma busulfan. Methods: Busulfan was separated and detected using an LC system containing a C18 column equipped with MS/MS. The sample was eluted with a mobile phase gradient for a total run time of 10 min. Plasma busulfan concentration was quantified against a 6-point standard curve in a multiple reaction monitoring mode at mass-to-charge ( m/z ) 264.1 > 151.1. Precision, recovery, matrix effect, linearity, detection capability, carryover, and sta- bility were evaluated. The range of plasma busulfan concentration was obtained by ana- lyzing samples from 9 children receiving busulfan. Results: The coefficients of variation of within-run and within-laboratory precision were all below 5%. Recoveries were all within the range of 100-105%. Linearity was verified from 0 to 5,000 ng/mL. Limit of detection and limit of quantification were 1.56 and 25 ng/mL, respectively. Carryover rate was within allowable limits. Plasma busulfan concentration was stable for 2 weeks at -20°C and -80°C, but decreased by 25% when the plasma was stored for 24 hr at room temperature, and by <5% in 24 hr at 4°C. The plasma busulfan concentrations were between 347 ng/mL and 5,076 ng/mL. Conclusions: Our method using LC-MS/MS enables highly accurate, reproducible, and rapid busulfan monitoring with minimal sample preparation. The method may also enable safe and proper dosage.
Abstract
Background: Busulfan, an alkylating agent administered prior to hematopoietic stem cell transplantation, has a narrow therapeutic range and wide variability in metabolism. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for rapid and accurate quantification of plasma busulfan. Methods: Busulfan was separated and detected using an LC system containing a C18 column equipped with MS/MS. The sample was eluted with a mobile phase gradient for a total run time of 10 min. Plasma busulfan concentration was quantified against a 6-point standard curve in a multiple reaction monitoring mode at mass-to-charge ( m/z ) 264.1 > 151.1. Precision, recovery, matrix effect, linearity, detection capability, carryover, and sta- bility were evaluated. The range of plasma busulfan concentration was obtained by ana- lyzing samples from 9 children receiving busulfan. Results: The coefficients of variation of within-run and within-laboratory precision were all below 5%. Recoveries were all within the range of 100-105%. Linearity was verified from 0 to 5,000 ng/mL. Limit of detection and limit of quantification were 1.56 and 25 ng/mL, respectively. Carryover rate was within allowable limits. Plasma busulfan concentration was stable for 2 weeks at -20°C and -80°C, but decreased by 25% when the plasma was stored for 24 hr at room temperature, and by <5% in 24 hr at 4°C. The plasma busulfan concentrations were between 347 ng/mL and 5,076 ng/mL. Conclusions: Our method using LC-MS/MS enables highly accurate, reproducible, and rapid busulfan monitoring with minimal sample preparation. The method may also enable safe and proper dosage.
참고문헌 (31)
- Nath CE, "Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring", Curr Clin Pharmacol, 2, pp.75~91 (2007)
- Ciurea SO, "Busulfan in hematopoietic stem cell transplantation", Biol Blood Marrow Transplant, 15, pp.523~536 (2009)
- Russell JA, "Therapeutic drug monitoring of busulfan in transplantation", Curr Pharm Des, 14, pp.1936~1949 (2008)
- Dean RM, "Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide", Br J Haematol, 148, pp.226~234 (2010)
- Lee JW, "Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling", Biol Blood Marrow Transplant, 18, pp.944~950 (2012)
- Gaziev J, "Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring", Blood, 115, pp.4597~4604 (2010)
- Paci A, "Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation", Ther Drug Monit, 34, pp.198~208 (2012)
- Méresse V, "Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children", Bone Marrow Transplant, 10, pp.135~141 (1992)
- Carreras E, "Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients", Biol Blood Marrow Transplant, 13, pp.1448~1454 (2007)
- Chen TL, "Determination of busulfan in human plasma by gas chromatography with electron-capture detection", J Chromatogr, 425, pp.303~309 (1988)
- Quernin MH, "Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol", J Chromatogr B Biomed Sci Appl, 709, pp.47~56 (1998)
- Bleyzac N, "Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma", J Chromatogr B Biomed Sci Appl, 742, pp.427~432 (2000)
- Peris JE, "Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection", J Chromatogr B Biomed Sci Appl, 730, pp.33~40 (1999)
- Courtney JB, "Determination of busulfan in human plasma using an ELISA format", Ther Drug Monit, 31, pp.489~494 (2009)
- Mürdter TE, "Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry", Clin Chem, 47, pp.1437~1442 (2001)
- Quernin MH, "Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children", J Chromatogr B Biomed Sci Appl, 763, pp.61~69 (2001)
- Kellogg MD, "Tandem mass spectrometry method for the quantification of serum busulfan", Ther Drug Monit, 27, pp.625~629 (2005)
- dos Reis EO, "Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography", electrospray ionization tandem mass spectrometry, 2005, pp.19, 1666~1674
- Bunch DR, "A fast and simple assay for busulfan in serum or plasma by liquid chromatography-tandem mass spectrometry using turbulent flow online extraction technology", J Chromatogr B Analyt Technol Biomed Life Sci, 878, pp.3255~3258 (2010)
- Ansari M, "A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography", tandem mass spectrometry, 2012, pp.26, 1437~1446
- Food and Drug Administration, "Guidance for Industry: Bioanalytical method validation", U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, ~ (2001)
- Clinical and Laboraotry Standards Institute, "User verification of performance for precision and trueness; Approved guideline", Clinical and Laboraotry Standards Institute, ~ (2005)
- Matuszewski BK, "Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS", MS, 2003, pp.75, 3019~3030
- NCCLS, "Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline", National Committee for Clinical Laboratory Standards, ~ (2003)
- International Conference on Harmonization, "Q2B: validation of analytical procedures: methodology", US FDA Federal Register, 62, pp.27463~27467 (1997)
- 이현지, "Elecsys Hepatitis B Surface Antigen Quantitative Assay: Performance Evaluation and Correlation with Hepatitis B Virus DNA during 96 Weeks of Follow-up in Chronic Hepatitis B Patients", Annals of Laboratory Medicine, 32(6), pp.420~425 (2012), 대한진단검사의학회
- Snyder ML, "Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS", MS), 2010, pp.603, 129~136
- Oechtering D, "Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry", J Chromatogr B Analyt Technol Biomed Life Sci, 838, pp.129~134 (2006)
- Hempel G, "Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan", J Clin Oncol, 25, pp.1772~1778 (2007)
- Cooper AJ, "Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction", Drug Metab Dispos, 36, pp.1546~1552 (2008)
- Versace F, "A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry", Anal Bioanal Chem, 404, pp.1831~1838 (2012)